bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.07.24.665437

Consensus DNA Inhibits p53 Aggregation but Fails to Rescue Mutants

Abstract

The tumor suppressor p53 plays a crucial role in regulating gene expression under cellular stress. Somatic mutations to its DNA-binding domain are common in lethal cancers and lead to lost regulatory function and pathological hallmarks, such as misfolded p53 aggregates and amyloid-like fibrils. Despite decades of these observations, the molecular determinants driving p53 aggregation and its role in cancer incidence, progression, and lethality remain poorly defined. Identifying these determinants, however, is critical for developing therapeutic interventions that modulate protein solubility in cancer and understanding disparities in cancer outcomes. Therefore, we investigated whether consensus DNA sequences that stabilize wild-type p53 are sufficient to regulate the aggregation of oncogenic p53 mutants with reduced binding affinities. Using a combination of probe-based and label-free spectroscopic and microscopic techniques, we examined how consensus (p21, Bax) and non-consensus (p21-scramble, Poly-GC) DNA oligonucleotides regulate the aggregation of wild-type p53 in comparison to three cancer-associated mutants (R248Q, R273H, and R175H). We find that equimolar p21 consensus sequences significantly inhibits wild-type p53 aggregation, while other DNA sequences do not. In contrast, oncogenic p53 mutants evaded DNA regulation of protein aggregation, and some oligonucleotides even enhanced aggregation at low concentrations, which suggests concentration-dependent DNA-p53 interactions. These findings emphasize that DNA response elements are sufficient for regulating wild-type p53 aggregation in solution. However, key somatic mutations in cancer promote aggregation at the expense of DNA-binding, directly leading to the loss of p53 solubility through biochemical interactions. Taken together, these observations suggest that potent regulators of p53 aggregation should aim to restore affinity between oncogenic p53 mutants and regulatory DNA to minimize the pathological hallmarks of lethal tumors. Significance StatementOur research investigates whether DNA sequences that bind tumor suppressor protein p53 regulate its aggregation behavior in wild-type and somatically mutated forms linked to cancer. While specific DNA sequences regulate p53 aggregation, protein mutations that reduce affinity for consensus DNA or destabilize p53s conformation result in persistent, likely dysfunctional aggregates, even in the presence of regulatory nucleotides. Unsurprisingly, p53 and its mutants exhibit increased aggregation when there is substantially more protein to DNA, suggesting insufficient regulatory DNA or excess unregulated p53 may inevitably lead to pathological aggregation. These findings clarify our understanding of p53s molecular behavior and suggest that cancer-linked somatic mutations enable p53 to evade DNAs regulatory effects and subsequently aggregate, leading to downstream losses in function.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Steinsaltz, M., Gomes, G.-N. W., Levine, Z. A.. 2025-07-26. Consensus DNA Inhibits p53 Aggregation but Fails to Rescue Mutants. https://doi.org/10.1101/2025.07.24.665437

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Design of colipids with controlled lateral distance of head group moieties for targeting strategies in the field of lipid-based nanoparticles

Lipid nanoparticles and liposomes are nanoparticle drug formulations which are firmly established in clinics. In order to expand their application and improve efficacy, surface modifications can be a key strategy, especially for cell specific targeting. Targeting can be achieved by integrating ligand functionalized lipids or lipidoids on the nanoparticle surface. In this case, not solely the targeting ligand itself, but also the structure of the whole targeting lipid/lipidoid can affect the interaction of the targeting ligand with the binding motive on cells. Especially, distal spacer structures between lipid anchor and ligand unit, often composed of polyethylene glycol chains, provide a certain distance of the ligand from the nanoparticle surface. A concept which is currently neglected is the control of the lateral distance between ligand structures on the nanoparticle. Herein we investigated the possibility to design lipidoids with a lateral spacer composed of polyethylene glycol units. We synthesized and characterized different lipidoids which provide a primary amine in the head group for possible ligand coupling. In our model lipidoids the head groups were functionalized with a paramagnetic probe to apply electron paramagnetic resonance (EPR) methods for the characterization of the lipidoid interaction with model nanoparticles, in our case liposomes. Continuous wave EPR was used to study the efficiency of the novel lipidoids to integrate into lipid bilayers of model liposomes, which was shown to depend on lipidoid structure and liposome composition. Furthermore, using double electron-electron resonance (DEER), we observed lipidoid conformational changes occurring upon integration into liposomes.

biophysics↗

Binding mechanisms of therapeutic antibodies to human claudin-18.2

Claudin-18.2 (CLDN18.2) is a tight junction component with highly restricted expression in the paracellular space of nonmalignant gastric epithelial cells. It becomes accessible on tumor cell surface during malignant transformation, making CLDN18.2 an attractive target for targeted therapies against gastric cancer. Recently, zolbetuximab has become the first FDA-approved monoclonal antibody that targets CLDN18.2 in advanced gastric cancer, and others like osemitamab have entered phase 3 clinical trials. However, the high-resolution structure of CLDN18.2 is lacking, and how CLDN18.2 is recognized by therapeutic antibodies remains undefined. Here, we report cryo-EM structures of human claudin-18.2 (hCLDN18.2) in complex with the Fab fragments of zolbetuximab and osemitamab, revealing the structure of hCLDN18.2 and its binding mechanism to the therapeutic antibodies. Further analyses reveal that three residues in the first extracellular loop of hCLDN18.2 that are different from human claudin-18.1 (hCLDN18.1) play a critical role in antibody binding. Our data elucidate the structural basis for selective binding of therapeutic antibodies to hCLDN18.2, which should aid rational design of next-generation immunotherapies targeting hCLDN18.2.

biophysics↗

Structural relationships between the SLC12 cotransporter C-terminal domain, universal stress proteins and adenylating enzymes

Several SLC12 cotransporters bind ATP in a cytoplasmic C-terminal domain (CTD). We analysed 16,192 CTD-containing SLC12 sequences and compared 42,845 representative structures to examine the relationship between this nucleotide site, universal stress proteins (USPs) and adenylating enzymes. In phosphorylated NKCC1, D891 and D927 lie near the ATP phosphate chain, while R801 and K889 form a basic phosphate-binding clamp. NKCC1 retains this arrangement, whereas KCC paralogs replace or lose several corresponding groups. In structural comparisons with USP and adenylating-enzyme references, both CTD lobes score between universal stress proteins and EC-annotated domains, and the two lobes form separate lineages that include bacterial transporters. Lobe-specific and nucleotide-frame comparisons place ATP in the corresponding structural region used for -phosphate chemistry by catalytic members of this fold. Published work on UspG provides a precedent for protein-bound AMP in a natural USP. In the examined SLC12 structures and USP models, candidate protein hydroxyls lack an in-line geometry for attack at ATP P. Protein adenylation would require a change in protein or nucleotide geometry, or a different acceptor. These results define a structural basis for testing conditional protein adenylation at SLC12 nucleotide sites. The required evidence is a covalent protein-AMP adduct, identification of its acceptor and measurement of the expected pyrophosphate coproduct, with soluble nucleotide analysis to distinguish accompanying ATP reactions.

biophysics↗